30‐day mortality following palliative radiotherapy

Patients dying a short time after receiving palliative radiation are unlikely to have received benefit and may experience harm. To monitor the potential for avoidable harm, 30‐day mortality following palliative radiation has been recommended for use as a quality indicator and the Royal College of Radiologist have recommended a rate of lower than 20%. At the Canterbury Regional Cancer and Haematology Service in Christchurch, New Zealand (CRCHS), we investigated 30‐day mortality and evaluated the prognostic value of the TEACHH model in our population.

[1]  K. Hopkins,et al.  Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial. , 2019, JAMA.

[2]  Michael Lock,et al.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial , 2019, The Lancet.

[3]  RobertI Miller,et al.  Toxicity following palliative radiation therapy for painful metastatic bone lesions. , 2018, Journal of Clinical Oncology.

[4]  Z. B. Anita,et al.  Palliative radiotherapy for advanced Cancer: Are we giving it to the right patient at the right time? , 2018, The Medical journal of Malaysia.

[5]  E. Bruera,et al.  Palliative radiation therapy in the last 30 days of life: A systematic review. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  K. Ding,et al.  Effect of Radiotherapy on Painful Bone Metastases: A Secondary Analysis of the NCIC Clinical Trials Group Symptom Control Trial SC.23 , 2017, JAMA oncology.

[7]  Ruth E Langley,et al.  Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial , 2016, The Lancet.

[8]  A. Yeung,et al.  Thirty-day mortality rate in oncology patients treated with palliative radiotherapy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Nieder,et al.  Palliative radiotherapy during the last month of life: Predictability for referring physicians and radiation oncologists. , 2015, Oncology letters.

[10]  A. Newsham,et al.  30 day mortality in adult palliative radiotherapy – A retrospective population based study of 14,972 treatment episodes , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  C. Nieder,et al.  Development and validation of a model predicting short survival (death within 30 days) after palliative radiotherapy. , 2014, Anticancer research.

[12]  J. Temel,et al.  Predicting life expectancy in patients with metastatic cancer receiving palliative radiotherapy: The TEACHH model , 2014, Cancer.

[13]  IMPROVING OUTCOMES: A STRATEGY FOR CANCER Assessment of the Impact on Equalities (AIE) Published alongside Improving Outcomes: A Strategy for Cancer , 2011 .

[14]  John H Suh,et al.  Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. , 2005, Journal of the National Cancer Institute.

[15]  J Kievit,et al.  The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[17]  D. Tong,et al.  The palliation of symptomatic osseous metastases final results of the study by the radiation therapy oncology group , 1982, Cancer.